<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39293298</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>26</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Defining long COVID using a population-based SARS-CoV-2 survey in California.</ArticleTitle><Pagination><StartPage>126358</StartPage><MedlinePgn>126358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.126358</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)01040-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">More than four years after the start of the COVID-19 pandemic, understanding of SARS-CoV-2 burden and post-acute sequela of COVID (PASC), or long COVID, continues to evolve. However, prevalence estimates are disparate and uncertain. Leveraging survey responses from a large serosurveillance study, we assess prevalence estimates using five different long COVID definitions among California residents.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The California Department of Public Health (CDPH) conducted a cross-sectional survey that included questions about acute COVID-19 infection and recovery. A random selection of California households was invited to participate in a survey that included demographic information, clinical symptoms, and COVID-19 vaccination history. We assessed prevalence and predictors of long COVID among those previously testing positive for SARS-CoV-2 across different definitions using logistic regression.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">A total of 2883 participants were included in this analysis; the majority identified as female (62.5&#xa0;%), and the median age was 39&#xa0;years (interquartile range: 17-55&#xa0;years). We found a significant difference in long COVID prevalence across definitions with the highest prevalence observed when participants were asked about incomplete recovery (20.9&#xa0;%, 95&#xa0;% confidence interval [CI]: 19.4-22.5) and the lowest prevalence was associated with severe long COVID affecting an estimated 4.9&#xa0;% (95&#xa0;% CI 4.1-5.7) of the participant population. Individuals that completed the primary vaccination series had significantly lower prevalence of long COVID compared to those that did not receive COVID vaccination.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">There were significant differences in the estimated prevalence of long COVID across different definitions. People who experience a severe initial COVID-19 infection should be considered at a higher probability for developing long COVID.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Centers for Disease Control and Prevention - Epidemiology and Laboratory Capacity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pry</LastName><ForeName>Jake M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>California Department of Public Health, Richmond, CA, USA; School of Medicine, University of California, Davis, CA, USA; Center for Infectious Disease Research in Zambia, Lusaka, Zambia. Electronic address: jmpry@ucdavis.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCullough</LastName><ForeName>Kalyani</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>California Department of Public Health, Richmond, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Kristina Wen-Jeh</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>California Department of Public Health, Richmond, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>California Department of Public Health, Richmond, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehrotra</LastName><ForeName>Megha L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>California Department of Public Health, Richmond, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamba</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>California Department of Public Health, Richmond, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Seema</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>California Department of Public Health, Richmond, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">California</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Long COVID-19</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">Public health</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>19</Day><Hour>0</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>19</Day><Hour>0</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>18</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39293298</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.126358</ArticleId><ArticleId IdType="pii">S0264-410X(24)01040-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>